TP53 and neoplasm: Almost all patients expressed KRAS mutations; however, the results demonstrated reduced T-cell response to vaccine-encoded, tumor-relevant KRAS neoantigens in favor of vaccine-encoded, tumor-irrelevant TP53-specific T-cell responses, suggesting a need to enhance antigen presentation.41 These results highlight important considerations for the development of future multiepitope shared neoantigen vaccines that may impact clinical efficacy.